Skip to main content

Study details rare heart risk of certain cancer therapies

Submitted by vicc_migrate on
Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of […]

Breast cancer program lands new research grants

Submitted by vicc_migrate on
Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. The grants totaling more than $3 million will fund mechanistic science and clinical trials designed to test novel therapy combinations and determine why some forms of breast cancer become resistant […]

Drivers of breast cancer metastasis

Submitted by vicc_migrate on
Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.

Investigators match novel cancer mutations with potential therapies

Submitted by vicc_migrate on
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]

Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram Cancer Center is at the forefront of new discoveries that help us prevent, find, treat, manage and cure cancer. But we can't make these discoveries alone. Our patients, caregivers, community leaders, donors, volunteers, and educators contribute their insight, time, and passion to advancing the discoveries that lead us closer to a cure.

No matter how cancer has touched your life, you are a key partner in our efforts to save lives and improve the quality of life for those with cancer. 

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

To learn more about any of our clinical
trials, call 615-936-8422.

Signal Transduction and Chemical Biology Research Program

The pathways that send chemical signals from the cell surface to the nucleus are major targets of genotype-driven therapies for cancer. The Signal Transduction and Chemical Biology Research Program aims to better understand how changes in tumor cells alter these signaling networks, and to identify—or create—molecules that target these pathways as potential new therapies for cancer.

Subscribe to